Herr et al. were able to significantly diminish the proliferation and metabolic activity of colorectal cancer cells in vitro combining various BRAF inhibitors with dual blockers of EGFR and ERBB2, like lapatinib [49]. This evidence concerns the gene ERBB2 and colorectal cancer.